Osteopontin and Clinical Outcomes in Hemodialysis Patients
Background/Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are significant public health issues, with cardiovascular morbidity and mortality being the leading causes of death in hemodialysis patients. Osteopontin (OPN), a multifunctional glycoprotein, has emerged as a po...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/11/2605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846154186937335808 |
|---|---|
| author | Claudia Torino Federico Carbone Patrizia Pizzini Sabrina Mezzatesta Graziella D’Arrigo Mercedes Gori Luca Liberale Margherita Moriero Cristina Michelauz Federica Frè Simone Isoppo Aurora Gavoci Federica La Rosa Alessandro Scuricini Amedeo Tirandi Davide Ramoni Francesca Mallamaci Giovanni Tripepi Fabrizio Montecucco Carmine Zoccali |
| author_facet | Claudia Torino Federico Carbone Patrizia Pizzini Sabrina Mezzatesta Graziella D’Arrigo Mercedes Gori Luca Liberale Margherita Moriero Cristina Michelauz Federica Frè Simone Isoppo Aurora Gavoci Federica La Rosa Alessandro Scuricini Amedeo Tirandi Davide Ramoni Francesca Mallamaci Giovanni Tripepi Fabrizio Montecucco Carmine Zoccali |
| author_sort | Claudia Torino |
| collection | DOAJ |
| description | Background/Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are significant public health issues, with cardiovascular morbidity and mortality being the leading causes of death in hemodialysis patients. Osteopontin (OPN), a multifunctional glycoprotein, has emerged as a potential biomarker for vascular disease in CKD due to its role in inflammation, tissue remodeling, and calcification. Methods: This cohort study included 1124 hemodialysis patients from the PROGREDIRE study, a registry involving 35 dialysis units in Southern Italy. Serum osteopontin levels were measured using enzyme-linked immunosorbent assay (ELISA). The primary endpoints were all-cause and cardiovascular mortality. Multivariate Cox regression analyses were performed to assess the association between osteopontin levels and mortality, adjusting for traditional risk factors, biomarkers of inflammation, nutritional status, and ESKD-related factors. Results: During a mean follow-up of 2.8 years, 478 patients died, 271 from cardiovascular causes. Independent correlates of osteopontin included alkaline phosphatase and parathyroid hormone. Elevated osteopontin levels were significantly associated with increased all-cause mortality (HR 1.19, 95% CI 1.09–1.31, <i>p</i> < 0.001) and cardiovascular mortality (HR 1.22, 95% CI 1.08–1.38, <i>p</i> = 0.001) after adjusting for confounders. Conclusions: Elevated osteopontin levels are associated with increased all-cause and cardiovascular mortality in hemodialysis patients. These findings implicate osteopontin in the high risk for death and cardiovascular disease in the hemodialysis population. Intervention studies are needed to definitively test this hypothesis. |
| format | Article |
| id | doaj-art-9e6a661aacc74676aff5a7ff1a4a3d87 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-9e6a661aacc74676aff5a7ff1a4a3d872024-11-26T17:53:24ZengMDPI AGBiomedicines2227-90592024-11-011211260510.3390/biomedicines12112605Osteopontin and Clinical Outcomes in Hemodialysis PatientsClaudia Torino0Federico Carbone1Patrizia Pizzini2Sabrina Mezzatesta3Graziella D’Arrigo4Mercedes Gori5Luca Liberale6Margherita Moriero7Cristina Michelauz8Federica Frè9Simone Isoppo10Aurora Gavoci11Federica La Rosa12Alessandro Scuricini13Amedeo Tirandi14Davide Ramoni15Francesca Mallamaci16Giovanni Tripepi17Fabrizio Montecucco18Carmine Zoccali19Clinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyClinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyClinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyClinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyCNR—Institute of Clinical Physiology, 00186 Rome, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyClinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyClinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, 89124 Reggio Calabria, ItalyFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, ItalyRenal Research Institute, New York, NY 10065, USABackground/Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are significant public health issues, with cardiovascular morbidity and mortality being the leading causes of death in hemodialysis patients. Osteopontin (OPN), a multifunctional glycoprotein, has emerged as a potential biomarker for vascular disease in CKD due to its role in inflammation, tissue remodeling, and calcification. Methods: This cohort study included 1124 hemodialysis patients from the PROGREDIRE study, a registry involving 35 dialysis units in Southern Italy. Serum osteopontin levels were measured using enzyme-linked immunosorbent assay (ELISA). The primary endpoints were all-cause and cardiovascular mortality. Multivariate Cox regression analyses were performed to assess the association between osteopontin levels and mortality, adjusting for traditional risk factors, biomarkers of inflammation, nutritional status, and ESKD-related factors. Results: During a mean follow-up of 2.8 years, 478 patients died, 271 from cardiovascular causes. Independent correlates of osteopontin included alkaline phosphatase and parathyroid hormone. Elevated osteopontin levels were significantly associated with increased all-cause mortality (HR 1.19, 95% CI 1.09–1.31, <i>p</i> < 0.001) and cardiovascular mortality (HR 1.22, 95% CI 1.08–1.38, <i>p</i> = 0.001) after adjusting for confounders. Conclusions: Elevated osteopontin levels are associated with increased all-cause and cardiovascular mortality in hemodialysis patients. These findings implicate osteopontin in the high risk for death and cardiovascular disease in the hemodialysis population. Intervention studies are needed to definitively test this hypothesis.https://www.mdpi.com/2227-9059/12/11/2605OPNhemodialysisclinical outcomescardiovascularmineral metabolismbiomarker |
| spellingShingle | Claudia Torino Federico Carbone Patrizia Pizzini Sabrina Mezzatesta Graziella D’Arrigo Mercedes Gori Luca Liberale Margherita Moriero Cristina Michelauz Federica Frè Simone Isoppo Aurora Gavoci Federica La Rosa Alessandro Scuricini Amedeo Tirandi Davide Ramoni Francesca Mallamaci Giovanni Tripepi Fabrizio Montecucco Carmine Zoccali Osteopontin and Clinical Outcomes in Hemodialysis Patients Biomedicines OPN hemodialysis clinical outcomes cardiovascular mineral metabolism biomarker |
| title | Osteopontin and Clinical Outcomes in Hemodialysis Patients |
| title_full | Osteopontin and Clinical Outcomes in Hemodialysis Patients |
| title_fullStr | Osteopontin and Clinical Outcomes in Hemodialysis Patients |
| title_full_unstemmed | Osteopontin and Clinical Outcomes in Hemodialysis Patients |
| title_short | Osteopontin and Clinical Outcomes in Hemodialysis Patients |
| title_sort | osteopontin and clinical outcomes in hemodialysis patients |
| topic | OPN hemodialysis clinical outcomes cardiovascular mineral metabolism biomarker |
| url | https://www.mdpi.com/2227-9059/12/11/2605 |
| work_keys_str_mv | AT claudiatorino osteopontinandclinicaloutcomesinhemodialysispatients AT federicocarbone osteopontinandclinicaloutcomesinhemodialysispatients AT patriziapizzini osteopontinandclinicaloutcomesinhemodialysispatients AT sabrinamezzatesta osteopontinandclinicaloutcomesinhemodialysispatients AT grazielladarrigo osteopontinandclinicaloutcomesinhemodialysispatients AT mercedesgori osteopontinandclinicaloutcomesinhemodialysispatients AT lucaliberale osteopontinandclinicaloutcomesinhemodialysispatients AT margheritamoriero osteopontinandclinicaloutcomesinhemodialysispatients AT cristinamichelauz osteopontinandclinicaloutcomesinhemodialysispatients AT federicafre osteopontinandclinicaloutcomesinhemodialysispatients AT simoneisoppo osteopontinandclinicaloutcomesinhemodialysispatients AT auroragavoci osteopontinandclinicaloutcomesinhemodialysispatients AT federicalarosa osteopontinandclinicaloutcomesinhemodialysispatients AT alessandroscuricini osteopontinandclinicaloutcomesinhemodialysispatients AT amedeotirandi osteopontinandclinicaloutcomesinhemodialysispatients AT davideramoni osteopontinandclinicaloutcomesinhemodialysispatients AT francescamallamaci osteopontinandclinicaloutcomesinhemodialysispatients AT giovannitripepi osteopontinandclinicaloutcomesinhemodialysispatients AT fabriziomontecucco osteopontinandclinicaloutcomesinhemodialysispatients AT carminezoccali osteopontinandclinicaloutcomesinhemodialysispatients |